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Background: Dalbavancin is a lipoglycopepetide antibiotic with activity against gram positive pathogens recently
approved for treatment of acute bacterial skin and skin structure infections. Pending the introduction of
antimicrobial susceptibility tests, we examined the utility of vancomycin inhibitory concentrations to predict
dalbavancin susceptibility in a panel of isolates obtained from phase 3 registration studies.
Findings: 99.6% of Staphylococcus aureus and 99.0% of beta-hemolytic streptococci which are susceptible to vancomycin
will have an MIC at or below the US FDA susceptibility breakpoint for dalbavancin.
Conclusion: Vancomycin should be considered as a surrogate for in vitro dalbavancin susceptibility testing.
Keywords: Susceptibility testing, Vancomycin, Dalbavancin, Antimicrobial agents, Acute bacterial skin and skin structure
infectionsWith the introduction of new antimicrobial agents
comes a need for diagnostic tests available in the com-
munity which can confirm the in vitro susceptibility of
target pathogens. Those diagnostic tests, however, re-
quire a significant amount of research and development
and can only be approved once the susceptibility break-
points for the agent are identified. Consequently, many
antibacterial agents newly available for clinical use are
not included in the automated testing systems com-
monly used in hospital settings.
Dalbavancin is a new lipoglycopeptide with activity
against Gram-positive pathogens that has a long half-life
allowing for infrequent dosing. Based on two phase 3 clin-
ical trials [1] dalbavancin was recently approved in the
United States for treatment of acute bacterial skin and
skin structure infections (ABSSSI) dosed intravenously as
1000 mg followed one week later by 500 mg [2] (USPI).
Antimicrobial susceptibility testing methodologies in
broth have been established by the Clinical and Labora-
tory Standards Institute [3] (CLSI) however commercially
available diagnostics are not presently available. In this* Correspondence: mdunne@duratatx.com
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unless otherwise stated.circumstance, the use of a surrogate agent to assess for
in vitro susceptibility is well precedented and has signifi-
cant utility pending the addition of the new antibacterial
agent to an established diagnostic testing susceptibility
platform [3,4].
Dalbavancin shares a similar mechanism of action with
vancomycin, though providing a significant enhance-
ment in potency, presumably a result of modification to
one of the side chains as well as the addition of a lipid
tail. The use of vancomycin as a surrogate for dalbavan-
cin in vitro susceptibility has been previously proposed
[5], and recently repeated [6] (R.N. Jones, D.J. Farrel, R.
K. Flamm, submitted for publication), based on a large
collection of isolates obtained from a hospital surveil-
lance program. Recently, in vitro susceptibility data,
derived from the DISCOVER clinical development pro-
gram has also become available that allows for cross
tabulation of mean inhibitory concentrations for these
two agents.
Findings
Isolates derived from patients enrolled in the dalbavancin
clinical development program for ABSSSI were tested for
susceptibility against dalbavancin and vancomycin. Identi-
fication of isolates was confirmed by MALDI BiotyperThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,






with 0.002% (v/v) polysorbate 80
Cation-adjusted
Mueller Hinton Broth
Inoculum Direct colony suspension,





to a 0.5 McFarland
standard
Incubation 35 +/− 2°C; ambient air;
24 hours
35 +/− 2°C; ambient
air; 24 hours
Solvent/diluent DMSO Water
Table 3 Cross tabulation of Beta-hemolytic streptococcal





<0.001 0.002 0.004 0.008 0.015 0.03 0.06 0.12 0.25




0.25 2 19 16 38 14 4 3 2
0.5 7 7 18 20 16 3 4
1 1 4 3 1
Table 4 Two patients with S. aureus isolates with a
dalbavancin MIC of 0.25 μg/ml
Characteristic Patient 1 Patient 2
Treatment Group Vancomycin/linezolid Dalbavancin
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luted in DMSO and susceptibility testing was performed
by broth microdilution in Cation-adjusted Mueller Hinton
Broth supplemented with 0.002% (v/v) polysorbate 80, as
described in CLSI M7, CLSI M100 and Eurofins Medinet
SOP [7] (1-P-PR-PRO-9002355– Broth Microdilution
MIC Testing with Frozen Panels). Quality control and in-
terpretations of results were performed according with
CLSI M100 with the reference strains Staphylococcus aur-
eus ATCC 29213 and Streptococcus pneumoniae ATCC
49619. Vancomycin testing was performed in a similar
manner, with differences as outlined in Table 1.
Of the 634 S. aureus isolates identified, the dalbavancin
MIC90 was 0.06 μg/ml. Three isolates (0.4%) had an
MIC greater than the FDA breakpoint of >0.12 μg/ml.
The MIC90 of S. aureus for vancomycin was 1 μg/ml
and no isolate had an MIC greater the breakpoint of
2 μg/ml. Cross tabulation of these susceptibility data
confirmed that 99.6% of the isolates that were suscep-
tible to vancomycin were also susceptible to dalbavancin
(Table 2).
Of the 192 beta-hemolytic streptococci, which include
S. pyogenes (87), S. agalactiae (36), S. dysgalactiae (4), S.
anginosus group (49), Group C streptococci (9) and Group
G streptococci (7), the dalbavancin MIC90 was 0.06 μg/ml.
Two isolates had an MIC >0.12 μg/ml. The two isolates
(1%) that would be considered non-susceptible to dalba-
vancin were both susceptible to vancomycin. Cross tabula-
tion of these susceptibility data confirmed that 99.0% ofTable 2 Cross tabulation of S. aureus isolates with mean





0.008 0.015 0.03 0.06 0.12 0.25
0.25 1
0.5 3 142 191 5 1
1 1 2 49 230 7 1
2 1the isolates that were susceptible to vancomycin were also
susceptible to dalbavancin (Table 3).
One patient treated with dalbavancin had an MIC that
would be considered non-susceptible (MIC = 0.25 μg/ml).
This organism was positive for the Panton-Valentine leu-
kocidin toxin and methicillin resistance and the patient
was a clinical success at Day 3 and a clinical cure at Day
14. The other patient with a dalbavancin MIC to S. aureus
of >0.12 μg/ml (MIC = 0.25 μg/ml) was treated with
vancomycin and was a clinical success (Table 4).
Staphylococcal and beta-hemolytic streptococcal iso-
lates were collected from two large clinical trials sup-
porting the development of dalbavancin for treatment of
ABSSSI. Based on recent epidemiologic surveys, the dis-
tribution of MICs in this collection is representative of
isolates circulating in hospitals in the United States [8].
99.6% of S. aureus and 99.0% of beta-hemolytic strepto-
cocci which are susceptible to vancomycin (MIC ≤ 2 μg/
ml) will have an MIC at or below the US FDA suscepti-
bility breakpoint for dalbavancin.
While vancomycin susceptible isolates were also sus-
ceptible to dalbavancin, no data are available regarding
the potential clinical outcome of patients treated with
dalbavancin who have isolates with an MIC toAge (years) 51 34
Type of infection Traumatic Wound
Infection
Cellulitis
Wound culture MSSA MRSA
Vancomycin MIC 1 0.5
PVL toxin Negative Positive
mecA gene Negative Positive
Clinical response at 48–72
hours
Responder Responder
Clinical outcome at Day 14 Success Success
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these patients have been observed in clinical trials and
have been successfully treated. While the FDA breakpoint
is 0.12 μg/ml, based to a large degree on the clinical out-
come data of a sufficient number of patients infected with
isolates at that MIC, a preliminary assessment of the
ECOFF calculations [9] for S. aureus suggests a breakpoint
of 0.25 μg/mL, as this is the highest MIC of organisms
lacking phenotypically expressed resistance [10]. A re-
assessment of the existing breakpoint will be enabled by
analysis of more patients treated with dalbavancin who
had organisms with an MIC > 0.12 μg/ml.
A strong correlation between vancomycin and dalba-
vancin in vitro susceptibility results was observed for
both sets of isolates. While broth microdilution method-
ologies to guide performance of in vitro susceptibility
testing have been published, these data support the pro-
posal that vancomycin can be used as a surrogate for
susceptibility testing of dalbavancin, pending the intro-
duction of dalbavancin into established diagnostic sus-
ceptibility testing platforms.
Over 99.6% of S. aureus and 99.0% of beta-hemolytic
streptococci which are susceptible to vancomycin (MIC ≤
2 μg/ml) will have an MIC at or below the US FDA sus-
ceptibility breakpoint for dalbavancin. Vancomycin should
be considered for use as a surrogate for in vitro dalbavan-
cin susceptibility testing.
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